Tim Hunt - Moving the Goalposts or Protecting Patients?

In this episode of Science From the Fringe, host Bryce Nickels speaks with Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), about cell and gene therapies and the difficult questions surrounding how they should be regulated by the FDA.

The episode follows a March conversation with cardiologist Anish Koka about Vinay Prasad’s controversial tenure at the FDA. Together, the two episodes explore a fundamental question: When patients have devastating diseases and few treatment options, should the FDA demand stronger evidence before approving new therapies—or accept greater uncertainty to give patients faster access to experimental treatments?

In the March episode, Koka defended Prasad’s efforts to strengthen the FDA’s evidentiary standards, arguing that greater scrutiny was necessary to protect patients from ineffective or harmful treatments—particularly in the rare-disease space, where patient desperation, financial incentives, and political pressure can complicate regulatory decisions.

Tim offers a different perspective. He argues that the FDA became too rigid in its demands for randomized controlled trials, effectively “moving the goalposts” for rare-disease therapies. He contends that traditional trials are often impractical or ethically problematic for small populations with rapidly progressive diseases and that patients should have a greater voice in determining acceptable levels of risk and uncertainty.

Bryce and Tim also discuss the scientific risks of genetically modifying embryos, the potential for human enhancement and eugenics, whether germline editing could ever be demonstrated to be safe and ethical, and ARM’s call for a 10-year moratorium on heritable human genome editing.

The episode concludes with Tim’s perspective on the future of regenerative medicine, from CAR-T therapies and rare diseases to potential treatments for autoimmune disorders, Parkinson’s disease, and other more common conditions.

(recorded July 21, 2026)

Timestamps

00:30 - Introduction
02:13 - The Alliance for Regenerative Medicine
04:04 - Cell and gene therapy explained
06:43 - Hunt’s criticism of the FDA
10:40 - How much evidence is enough?
14:24 - Did the FDA “move the goalposts”?
19:15 - Biotech incentives and public trust
20:07 - The role of patients in FDA decisions
27:01 - Protecting patients vs. regulatory flexibility
30:04 - Political pressure on the FDA
31:56 - Heritable human genome editing
36:34 - The case for a 10-year moratorium
39:17 - Germline editing and eugenics
41:44 - Editing human embryos
43:06 - The ethics of engineering future generations
46:18 - The future of cell and gene therapy

Intro and outro by Tess Parks